title: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.
abstract: In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 microg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.
authors.affiliation: Division of Infectious Diseases (7811), Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.
authors.forename: Qiu N
authors.initials: QN
authors.lastname: Sun
authors.forename: Annette W
authors.initials: AW
authors.lastname: Fothergill
authors.forename: Dora I
authors.initials: DI
authors.lastname: McCarthy
authors.forename: Michael G
authors.initials: MG
authors.lastname: Rinaldi
authors.forename: John R
authors.initials: JR
authors.lastname: Graybill
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D005658:Fungi / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000382:microbiology; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B